Please login to the form below

Not currently logged in
Email:
Password:

balugrastim

This page shows the latest balugrastim news and features for those working in and with pharma, biotech and healthcare.

EMA backs 15 new medicines for use in EU

EMA backs 15 new medicines for use in EU

tilmanocept) for the delineation and localisation of sentinel lymph nodes; and Teva's Egranli (balugrastim) to treat chemotherapy-induced neutropenia.

Latest news

  • Teva withdraws US filing for cancer biologic Teva withdraws US filing for cancer biologic

    FDA requests more data for balugrastim. Teva said this week it is "assessing its options" after withdrawing the US drug filing for long-acting white cell stimulator balugrastim. ... The FDA has agreed to work with Teva in designing any additional studies

  • Neulasta rival from Teva cleared in EU Neulasta rival from Teva cleared in EU

    Teva's biologics pipeline also includes reslizumab, a monoclonal antibody targeting interleukin-5 (IL-5) in phase III for moderate-to-severe asthma, and an albumin-fused G-CSF called balugrastim

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hanson Zandi

Hanson Zandi is a Creative and Digital Healthcare Agency. We combine 30 years’ experience with the enthusiasm of a start-up...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics